Literature DB >> 28629907

The role of biosimilar manufacturers in improving access to insulin globally.

Christophe Perrin1, Margaret Ewen2, David Beran3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28629907     DOI： 10.1016/S2213-8587(17)30218-8

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  6 in total

Review 1.  Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.

Authors:  David Beran; Margaret Ewen; Kasia Lipska; Irl B Hirsch; John S Yudkin
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

2.  A perspective on global access to insulin: a descriptive study of the market, trade flows and prices.

Authors:  D Beran; R O Laing; W Kaplan; R Knox; A Sharma; V J Wirtz; J Frye; M Ewen
Journal:  Diabet Med       Date:  2019-04-07       Impact factor: 4.359

3.  Insulin prices, availability and affordability in 13 low-income and middle-income countries.

Authors:  Margaret Ewen; Huibert-Jan Joosse; David Beran; Richard Laing
Journal:  BMJ Glob Health       Date:  2019-06-11

4.  [Insulin: prices, availability, and affordability in public and private Peruvian pharmaciesPreço, disponibilidade e acessibilidade à insulina em farmácias públicas e privadas no Peru].

Authors:  Janeth Tenorio-Mucha; María Lazo-Porras; Liliana Hidalgo-Padilla; David Beran; Margaret Ewen
Journal:  Rev Panam Salud Publica       Date:  2019-10-31

Review 5.  A global perspective on the issue of access to insulin.

Authors:  David Beran; Maria Lazo-Porras; Camille M Mba; Jean Claude Mbanya
Journal:  Diabetologia       Date:  2021-01-23       Impact factor: 10.122

6.  The insulin market reaches 100.

Authors:  David Beran; Edwin A M Gale; John S Yudkin
Journal:  Diabetologia       Date:  2022-03-11       Impact factor: 10.460
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.